MedTrace Logo

A Study of an Investigational Regimen Combining FDA Approved HIV Drugs in HIV-Infected Subjects

NCT00363142 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 211

Last updated 2010-11-05

Study results available
· View outcomes & findings →

Summary

This is a 24-week study to evaluate the efficacy and safety of a once-daily ritonavir-boosted fosamprenavir regimen (1400mg/100mg QD) to a 200mg ritonavir-boosted fosamprenavir regimen administered either twice-daily or once-daily.

Conditions

  • HIV Infection
  • Infection, Human Immunodeficiency Virus

Interventions

DRUG

Half-boosted Fosamprenavir

Once daily, reduced dose ritonavir-boosted fosamprenavir

DRUG

Full Boosted Fosamprenavir

Full ritonavir-boosted fosamprenavir

Sponsors & Collaborators

Principal Investigators

  • GSK Clinical Trials · GlaxoSmithKline

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-05-31
Primary Completion
2008-06-30
Completion
2008-06-30

Countries

  • United States
  • Puerto Rico

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00363142 on ClinicalTrials.gov